VACCINATION is widely applied to control infectious bovine rhinotracheitis (IBR) . Eradication programmes that make use of glycoprotein E (gE) deletion mutants of bovine herpesvirus type 1 (BHV-1), so called IBR marker vaccines (Kaashoek and van Oirschot 1996) , have been initiated in a number of countries in the European Union (EU) (Bätza 2003) .
Before they were licensed, the currently available live IBR marker vaccines were tested in field studies (Mars and others 2001; J. Földi, personal communication) . These field studies were performed under well controlled conditions on farms that typically had a high standard of hygiene and animal health management. Because the level of herd management might influence the success of any vaccination programme, it was decided to study the performance of a live IBR marker vaccine under field conditions in three EU countries, Germany, Italy and Hungary, with different farming conditions and different approaches to the eradication of IBR. This paper reports the findings of the three studies.
MATERIALS AND METHODS
A different study design was followed in each of the three countries. The vaccinations and testing performed in the German study had to comply with the German BHV-1 directive, which has been in place since 1997. Italy does not have a national IBR eradication programme, but there are voluntary programmes at regional level and compulsory programmes in some provinces. The Italian study formed part of a voluntary eradication programme. The Hungarian study covered the first period after the introduction of a national eradication programme. As part of this programme, farm owners had to screen their herds for BHV-1 seroprevalence, and then submit an eradication plan containing the proposed vaccination programme and control measurements for approval to the country's state veterinary service.
Vaccine
Commercial batches of the same live IBR marker vaccine (Bovilis IBR Marker; Intervet International) were used in all three studies. The animals were vaccinated with a 2 ml dose containing at least 10 5·7 TCID50; the vaccination schedules are described below. The performance of a live marker vaccine for bovine herpesvirus type 1 (BHV-1) was studied in the field in three European Union countries with different farming conditions. The progress in the eradication of the virus was followed in a large herd in Germany and one in Italy, and a major serological survey involving 147 farms was conducted in Hungary. Commercial batches of the same vaccine were used in all three studies. The herds were vaccinated according to agreed protocols and the animals' BHV-1 antibody status was determined at local institutes by using commercial glycoprotein B (gB)-and glycoprotein E (gE)-ELISAs. In all three studies, the seroprevalence of BHV-1 gE decreased progressively. Given the starting conditions and the long duration of the studies, reactivation events and virus circulation would have been more likely to have occurred if the herds had not been vaccinated. Hungary A national BHV-1 eradication programme began in Hungary in 2002. At the same time, a serological survey was offered to farms planning to use an IBR marker vaccine. This survey included a screening examination at the start of the programme and monitoring examinations during the course of the programme. Within each herd, the sample size was calculated to determine whether the infection rate was below or above a 25 per cent limit, with 99 per cent confidence, at screening, while the limit was set to 10 per cent during monitoring. Between 2002 and February 2006, data were collected from 147 farms distributed all over Hungary. Before the study began, the farms had either not implemented any BHV-1 control measures or used conventional non-marker vaccines. Most of the farms were dairy farms, with an average size of 500 animals (range 80 to 1800). The following categories of animals were defined: calves (up to six months but mostly three to five months of age), some of which may have had maternally derived antibody; maiden heifers (between six and 15 to 18 months of age); pregnant heifers (approximately 18 to 26 months of age); and cows (over 26 months of age).
Antibody ELISAs
After the initial BHV-1 serological evaluation, the live IBR marker vaccine was used as follows. In herds with a low seroprevalence in the youngstock (heifers and pregnant heifers), all the cattle aged five months or more were vaccinated once intramuscularly and revaccinated every six months. In herds with a high seroprevalence in the youngstock, it was advised that calves should be vaccinated intranasally at two weeks of age or shortly afterwards, revaccinated intramuscularly at four months of age and thereafter boosted every six months. It was also advised that cattle of different age groups should, as far as possible, be segregated, and that pregnant heifers in particular should be kept separately from the dry cows.
Before the vaccination programme began, more than 6500 samples were tested for BHV-1 antibodies, mostly by means of either a locally produced indirect ELISA (National Veterinary Institute) or a commercially available blocking gB ELISA (HerdChek BHV-1 gB ELISA; IDEXX), or in a few cases by a virus neutralising antibody test. Three state laboratories and two private laboratories were involved in the screening.
The monitoring programme collected more than 2600 samples, which were tested by means of a commercial gE ELISA (HerdChek anti gE ELISA; IDEXX) 18 to 36 months after the start of the vaccination programme, targeted mainly at the age group(s) exposed to IBR infection within the herd, that is, animals in contact with previous IBR-infected animals (heifers, pregnant heifers and first-parity cows).
RESULTS

Germany
During the first year of the vaccination programme, some new seroconversions were detected in animals of all age groups and in all the housing units, but in the following years, the incidence of new seroconversions decreased from 16·4 per cent in 2003 to 0·1 per cent (only one animal) in 2005 (Fig 1) . As a result, the herd seroprevalence decreased from 31·7 per cent in the first quarter of 2003 to 23·1 per cent in the first quarter of 2004 and 5·9 per cent in the fourth quarter of 2005 in the production herd of milking cows and heifers.
In autumn 2006, three-and-a-half years after the eradication programme began, the herd was certified free of BHV-1.
Italy
The gE seroprevalence in animals older than 12 months of age decreased progressively during the observation period, from 25·7 per cent in April 2003 to 11 per cent at the last control in October 2005 (Fig 2) . Among the animals less than (Table 1) , and they remained positive at the later testing. After April 2003, individual calves were found gE-positive because they had mistakenly been given colostrum from gE-positive cows; they were all found to be seronegative at subsequent controls. During the observation period, no respiratory or reproductive problems referrable to BHV-1 infection were observed. Moreover, no new gE-positive animals were detected during the monitoring period, indicating that no reactivation of latently infected animals had occurred.
Hungary
The seroprevalence of BHV-1 field virus decreased in all the categories of animals (Table 2) ; the decreases were greater in the older age groups (from 23 per cent to six per cent in maiden heifers, from 39 per cent to 8 per cent in pregnant heifers and from 71 per cent to 17 per cent in cows) than in the calves (46 per cent before and 31 per cent after the vaccination programme). Data were available from 18 farms to follow the seroprevalence directly in sample groups of one or more age categories (Table 3 ). The number of farms that were free of BHV-1 (as judged by the results in the sample group) in a certain age category increased from three to eight (out of 12) for the heifers, from one to five (out of six) for the pregnant heifers, and from zero to 10 (out of 13) for the cows.
DISCUSSION
These results suggest that the live IBR marker vaccine was effective under field conditions in each of the three countries. The efficacy of the vaccine had previously been demonstrated, under experimental conditions, in terms of the reduction in clinical signs and virus excretion after intranasal challenge with a high dose of virulent field virus (Makoschey and Keil 2000, Patel and others 2004) . However, a vaccine intended for the eradication of a virus should effectively stop the circulation of the field virus; this depends not only on the reduction of the excretion of the field virus but also on the reduction in the susceptibility of the animals to the infection. This factor is not investigated in a vaccination-challenge study. An experimental design and mathematical model has been developed to determine the reproduction ratio after vaccination against the pseudorabies virus (Bouma and others 1997) . However, a third factor affecting the efficacy of a vaccine is not investigated in laboratory transmission studies: the effect of the potential reactivation of latently infected viruses. The capacity of herpesviruses to become latent and to be reactivated later is a very effective mechanism to promote their long-term survival in a cattle population. The reduction of reactivation and re-excretion are therefore important for the eradication of BHV-1. In the German study, this factor was covered by giving the cows a booster vaccination in the period before they calved, a known risk period for the re activation of latent virus.
The vaccine used in these studies has been licensed for use in cattle from the age of two weeks onwards. In general, maternal immunity should provide sufficient protection during the first month of life, and vaccination is typically started at the age of three months (as in the German study) or four months (as in the Italian study). The results of these two studies indicate that maternally derived antibody prevented infections very efficiently. However, under conditions with a very high infectious pressure, it might be preferable to start vaccination at the age of two weeks. In the Hungarian study, the farms with a high seroprevalence were advised to follow this practice.
The currently available live IBR marker vaccines were tested in field studies before they were licensed (Mars and others 2001, J. Földi, personal communication) . Those studies were performed according to previously established protocols under well controlled conditions on farms that typically had high standards of hygiene and animal health management. In contrast, the present studies did not include negative control groups. This was partly for practical reasons; for example, in the German study the vaccination of all the animals was mandatory. In addition, the inclusion of unvaccinated sentinel animals would have led to an underestimation of the efficacy of the vaccine, because the unvaccinated animals would have increased the infectious pressure in comparison with circumstances in which all animals were vaccinated.
However, it is well understood that the lack of an unvaccinated control group complicates the conclusions about the extent of the field challenge. The reproduction ratios of BHV-1 field virus in an unvaccinated population differ between studies (Hage and others 1996 , Bosch and others 1998 , Mars and others 2001 , but all the estimated values are well above 1, indicating that each infected animal would infect at least one more animal. In the German study, the number of new seroconversions steadily decreased, showing that although there was field virus circulating throughout the observation period, the vaccination programme effectively contained the spread of the virus.
In the Italian study, there was field virus circulating at least until shortly before the vaccination programme started, because three calves were found positive for gE in April 2003 The survey in Hungary was carried out at the beginning of the national eradication programme. Before that programme started, the farms had either not implemented any BHV-1 control measures or had used conventional nonmarker vaccines. Farms using conventional non-marker IBR vaccines were considered to be positive and screening was therefore voluntary for them. The study covered a period of 24 to 42 months. Given the starting conditions, the time span and the seroprevalences at the beginning of the survey, reactivation events would most likely have occurred on at least some of the farms. However, the seroprevalence did not increase in any of the categories of animals on any of the farms from which detailed results were available for one or more age groups.
Previous serological surveys have shown that the prevalence of BHV-1 in large herds is not homogenous between age groups; typically, the seroprevalence in the older animals is higher than in the heifers. On the other hand, the effect of vaccination on the seroprevalence in the calves is typically biased by the presence of residual maternally derived antibody. The different age groups were therefore studied separately in the Italian study and the Hungarian survey. The results confirm the difference in prevalence for the different age groups. However, the eradication of BHV-1 proceeded consistently in all the age groups. It can be concluded that vaccination with the live IBR marker vaccine contributed significantly to the eradication of BHV-1 under field conditions in three countries with very different farming conditions.
